Quantifying impact of accelerated approval on life extension

Accelerated approval has provided massive benefits to cancer patients, contributing over 260,000 additional life years from 2006 to 2022, according to a study published in the Journal of the National Comprehensive Cancer Network. That number is far from firm, and is almost certainly an underestimate.

Documenting the benefits from accelerated approval could help defend the pathway against academic critics, and counter misleading research that has led medical journals and news organizations to inaccurately report that a large proportion of accelerated approval cancer drugs have not extended survival. ...